Yuhan Corporation Signs Contract to Acquire Targeted Anticancer Drug Candidate... Worth 430 Billion KRW

JY INTS BIO HER2 Target 'JIN-A04'
"The First Step Toward 2nd and 3rd Reklaza"

Yuhan Corporation is investing 430 billion KRW to acquire a targeted anticancer drug candidate from a domestic bio company.

At the technology transfer contract ceremony between Yuhan Corporation and Jints Bio held on the 30th, Jo Wook-je, CEO of Yuhan Corporation (left), and Jo Anna, CEO of Jints Bio, are taking a commemorative photo.
[Photo by Yuhan Corporation]

On the 30th, Yuhan Corporation announced that it has signed a technology license agreement for 'JIN-A04,' a tyrosine kinase inhibitor (TKI) targeting human epidermal growth factor receptor (HER)2, with J-INT Bio.

The total contract value is approximately 429.8 billion KRW, including an upfront payment of 2.5 billion KRW and milestone payments based on future development, approval, and sales.

JIN-A04 is an oral TKI drug candidate targeting the HER2 gene in non-small cell lung cancer, and according to Yuhan Corporation, there are currently no approved oral drugs targeting this. Previously, J-INT Bio presented preclinical results of JIN-A04 at the 2023 American Association for Cancer Research (AACR) conference, revealing strong efficacy in both in vitro and in vivo studies.

Jo Wook-je, CEO of Yuhan Corporation, said, "With this contract, we believe we have taken a step forward in securing an additional anticancer drug pipeline for the development of the second and third generations of Reklaza. We will focus all our capabilities to quickly enter clinical trial phases and plan to further strengthen our anticancer drug pipeline."

Joanna, CEO of J-INT Bio, stated, "We expect JIN-A04 to bring hope to non-small cell lung cancer patients with the 'HER2 Exon20 insertion' mutation."

Meanwhile, Yuhan Corporation invested 2 billion KRW each in 2021 and 2022 in J-INT Bio, holding a 14.8% stake.

This content was produced with the assistance of AI translation services.